Top PDF BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.
... early-stage non-small-cell lung cancer (NSCLC) is considered a potentially curable disease following complete resection, patients have a wide spectrum of survival according to stage ...
7
THROMBOCYTOSIS AS PROGNOSTIC FACTOR FOR SURVIVAL IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED WITH FIRST- LINE CHEMOTHERAPY.
... increase in platelet count may promote tumor cells growth and ...growth factor (VEGF) and platelet- derived growth factor (PDGF), during blood ...role in regulating angio- genesis. The ...
5
Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis.
... needed. In addition, an important issue that needs to be taken into account is the type of adjuvant therapy that each patient received because chemother- apy and/or therapies that target the epidermal growth ...
8
The Hemoglobin Level as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer Treated with Gemcitabine and cis-Platinum
... difference in outcome among patients with the same clinical stage of the disease suggests that advanced NSCLC is a heterogeneous disease and the survival depend of some patients characteristics as anemia, platelet ...
4
Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
... Recently study revealed that CEA level change during EGFR-TKIs therapy can be used to a predictor of survival.[22] However, LMR change (MBR) during EGFR-TKIs was seldom men- tioned before. Our study revealed patients ...
13
Analysis of Prognostic Factors in 541 Female Patients with Advanced Non-small Cell Lung Cancer
... increase in the incidence of lung cancer in women in re- cent years, it has brought broad concerns with its unique clinical and epidemiological characteristics and beter ...advanced ...
6
Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer.
... up-regulated in our study were MARS, MRPL3, PABPC1 and ...catalyst in the binding of methionine to its corresponding ...reported in human colon cancer ...shown in breast cancer ...
12
Potential role of immunotherapy in advanced non-small-cell lung cancer
... ushered in a new era with respect to the treatment of advanced non-small-cell lung ...growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) ...
10
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.
... Lung cancer remains the most dominant cause of cancer-related death in spite of advances in treatment strategies ...seen in patients within the same ...more novel ...
15
Proportional weight loss in six months as a risk factor for mortality in stage IV non- small cell lung cancer
... as prognostic markers of 3-month survival after diagnosis of stage IV non-small cell lung cancer ...a cancer treatment center in southern Brazil between January of ...
5
Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR.
... was prognostic of inferior survival. In addition, our optimal cutpoint analysis suggests that there is a clear threshold ...5.1% in squamous cell ...reported in other manuscripts ...
8
Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients.
... useful in patients with an increased pre-treatment level ...reduction in serum concentration during a therapy but was not a sign for disease remission [31] and thymidine kinase was unable to discriminate ...
10
The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis.
... only in full ...included in the article directly or calculated from the survival ...inaccuracy in the extracted survival ...strategies in these studies have different impact on overall ...
6
Albumin and Neutrophil Combined Prognostic Grade as a New Prognostic Factor in Non-Small Cell Lung Cancer: Results from a Large Consecutive Cohort.
... cohort. The optimal cut-off points were found out from ROC curve which is now widely recog- nized as the best approach for measuring the quality of diagnostic system. To ensure the best accuracy and diagnostic effect, ...
14
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
... growth factor receptor (EGFR), member of the human epidermal growth factor receptor (HER) family, plays a critical role in regulating multiple cellular processes including proliferation, ...
22
Clinics vol.68 número5
... resection in patients with stage I ...prognoses. In addition, patients with both pre-operative hypoalbuminemia and post-operative hypoal- buminemia had worse ...independent prognostic factors for RFS ...
8
Involvement of TRPC channels in lung cancer cell differentiation and the correlation analysis in human non-small cell lung cancer.
... isoform in different type of cancer cells or tissues are variable, suggesting the contribution or biological importance of each TRPC isoform in different cancer type could be ...negative ...
11
MicroRNA-dependent regulation of transcription in non-small cell lung cancer.
... implicated in relevant biological processes (according to gene ontology) in lung ...down-regulated in adenocarcinoma, are involved in several critical cell functions such as ...
13
PDF PT Jornal Brasileiro de Pneumologia 1 1 portugues
... Uma análise do estadiamento internacional para o câncer do pulmão, utilizado mundialmente nos últimos dez anos, mostrou problemas em duas áreas. O primeiro problema diz respeito ao mapa dos linfonodos mediastinais criado ...
2
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
... oligoprogression), in which the central nervous system (CNS) or other extra-CNS sites may be the main locations of progression ...(64). In sites such as the brain and bone, local therapy options (surgical ...
11
